Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06649682
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-15
Brief Title:
68Ga-NYM096177Lu-NYM096 in Metastatic CcRCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Safety Tolerability Imaging Characteristics and Efficacy of 68Ga-NYM096177Lu-NYM096 in the Treatment of Patients with Metastatic Clear Cell Renal Cell Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NYCRRLT
Brief Summary:
This is a single-center phase I study Patients with metastatic clear cell renal cell carcinoma will be recruited in this study to Phase A evaluate using 68Ga-NYM096 PETCT and to Phase B treat with 177Lu-NYM096
The study will be conducted in two phases The purpose is Phase A to evaluate the safety tolerability and imaging characteristics of 68Ga-NYM096 Phase B to evaluate the safety tolerability and recommended phase 2 dose of 177Lu-NYM096
The study will be conducted in two phases The purpose is Phase A to evaluate the safety tolerability and imaging characteristics of 68Ga-NYM096 Phase B to evaluate the safety tolerability and recommended phase 2 dose of 177Lu-NYM096
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None